Business Context and Reporting Period
This Form 8-K Current Report was filed by AtriCure, Inc. on December 4, 2019. The report discloses corporate governance changes effective as of the filing date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the appointment of new directors.
Material Changes
The Board of Directors appointed two new independent directors effective December 4, 2019:
- Karen Prange: Former Executive Vice President and CEO of the Global Animal Health, Medical and Dental Surgical Group at Henry Schein. She previously held leadership roles at Boston Scientific and Johnson & Johnson.
- Daniel Florin: Executive Vice President at Zimmer Biomet Holdings (appointed July 2019). He previously served as CFO and Interim CEO at Zimmer Biomet and held senior roles at Biomet, Boston Scientific, and CR Bard.
Both directors are deemed independent under NASDAQ listing standards. They will receive compensation in accordance with the Company's policies for non-employee directors.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It confirms there are no undisclosed transactions or arrangements between the Company and the new directors requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the independence status of Karen Prange and Daniel Florin against current NASDAQ listing standards.
- Review the Company's 2019 Proxy Statement to confirm the specific compensation structure for non-employee directors.
- Confirm the effective date of the appointments aligns with the Board meeting minutes.
- Check for any subsequent filings regarding the resignation of existing directors to make room for these appointments.